万泰生物：九价HPV疫苗启动男性III期临床试验并完成首例受试者入组

Core Viewpoint - Wantai Biological has initiated a Phase III clinical trial for its nine-valent HPV vaccine in males, marking a significant step in expanding its vaccine portfolio [1] Group 1: Company Developments - The company received approval from the National Medical Products Administration in November 2024 for the clinical trial of the nine-valent HPV vaccine [1] - The Phase III clinical trial has commenced, and the first subject has been enrolled [1]